This invention is related to substituted 2-aminoacetamides represented by Formula II: ##STR1## or a pharmaceutically acceptable salt or prodrug thereof, wherein: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; R.sub.5, R.sub.6 and R.sub.7 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl, or R.sub.5, is defined as above, and R.sub.6 and R.sub.7 together with the nitrogen atom to which they are attached form a heterocycle, including piperidine, piperazine, morpholine; A.sub.1 and A.sub.2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR.sub.8, CH.sub.2, C(O), NR.sub.8 C(O), C(O)NR.sub.8, SO, SO.sub.2 or a covalent bond; where R.sub.8 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; n is 0, 1, 2 or 3. The invention also is directed to the use substituted 2-aminoacetamides for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

Esta invención se relaciona con 2-aminoacetamides substituido representado por Formula II: ## del ## STR1 o una sal o un prodrug farmacéutico aceptable de eso, en donde: R.sub.1, R.sub.2, R.sub.3 y R.sub.4 son independientemente hidrógeno, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl o carboxyalkyl; R.sub.5, R.sub.6 y R.sub.7 son independientemente hidrógeno, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl o carboxyalkyl, o R.sub.5, se definen como arriba, y R.sub.6 y R.sub.7 junto con el átomo del nitrógeno a el cual son forma unida al heterocycle, incluyendo el piperidine, piperazine, morpholine; A.sub.1 y A.sub.2 son independientemente el carbocycle saturado o parcialmente no saturado del aryl, del heteroaryl, o el heterocycle saturado o parcialmente no saturado, cualesquiera de los cuales se substituyen opcionalmente; X es uno u O, S, NR.sub.8, CH.sub.2, C(O), NR.sub.8 C(O), C(O)NR.sub.8, ASÍ PUES, SO.sub.2 o un enlace covalente; donde está hidrógeno, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl R.sub.8, alkoxyalkyl o carboxyalkyl; n es 0, 1, 2 o 3. La invención también se dirige al 2-aminoacetamides substituido uso para el tratamiento del daño neuronal que sigue isquemia global y focal, para el tratamiento o la prevención de condiciones neurodegenerative tales como esclerosis de lateral amyotrophic (ALS), y para el tratamiento, la prevención o el mejoramiento del dolor, como anticonvulsivos, y como deprimentes antimanic, como anestésicos locales, como antiarrhythmics y para el tratamiento o la prevención de la neuropatía diabética.

 
Web www.patentalert.com

< (none)

< Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient

> Unsaturated hydroximic acid derivatives as per abstract inhibitors

> (none)

~ 00055